Product Datasheet  
DPYD Antibody  
Catalog Number: 32346  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Rabbit
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot:Q12882
    NCBI Gene ID:1806
  • Form of Antibody：  
  • Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • Storage：  
  • Store at -20˚C
  • Immunogen：  
  • Recombinant protein of human DPYD.
  • reactivity：  
  • Hu Ms Rt
  • appl_detail：  
  • Western blotting: 1:500 - 1:2000
    Immunohistochemistry: 1:50 - 1:100
  • other_names：  
  • DHP; DPD; DHPDHASE;
  • Purification：  
  • Antibodies were purified by affinity purification using immunogen.
  • Specificity：  
  • The antibody detects endogenous level of total DPYD protein.
  • Applications：  
  • WB IHC
  • Background：  
  • Dihydropyrimidine dehydrogenase (DPD, DPYD) catalyzes the initial and rate-limiting step in uracil and thymidine catabolism as well as catabolism of the chemotherapeutic drug 5-fluorouracil (5-FU) and its derivatives. DPYD deficiency, which results from mutations in the DPYD gene, causes errors in pyrimidine metabolism and potentially life-threatening side effects in cancer patients treated with 5-FU (reviewed in 1). As a result, ongoing work examines whether or how DPYD gene variation and protein expression can be used to predict 5-FU toxicity (1,2). Several genes that impart resistance to 5-FU were recently identified in human hepatocellular carcinoma (HCC). AEG-1, which is highly expressed in HCC, increases the expression of DPYD. DPYD is expressed more highly in HCC than in normal liver, and this is thought to be one mechanism of 5-FU resistance (3,4).



 
© Signalway Biotechnology All Rights Reserved.